The PI3K pathway is frequently activated in metastatic prostate cancer, most commonly through deletion or mutation of key negative regulator PTEN, which is altered in up to 50% of metastatic PCa [20, 23, 57, 58] and associated with poor prognosis [59]. This evidence concerns the gene PTEN and metastatic prostate carcinoma.